183 related articles for article (PubMed ID: 33619409)
1. Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems.
Schalbetter SM; Mueller FS; Scarborough J; Richetto J; Weber-Stadlbauer U; Meyer U; Notter T
Lab Anim (NY); 2021 Mar; 50(3):69-75. PubMed ID: 33619409
[TBL] [Abstract][Full Text] [Related]
2. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
Elife; 2023 Mar; 12():. PubMed ID: 36892930
[TBL] [Abstract][Full Text] [Related]
3. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
[TBL] [Abstract][Full Text] [Related]
4. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
5. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
[TBL] [Abstract][Full Text] [Related]
6. G
Marciante AB; Farmer GE; Cunningham JT
J Neurophysiol; 2020 Aug; 124(2):591-609. PubMed ID: 32697679
[TBL] [Abstract][Full Text] [Related]
7. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
eNeuro; 2016; 3(5):. PubMed ID: 27822508
[TBL] [Abstract][Full Text] [Related]
8. Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors.
Ji B; Kaneko H; Minamimoto T; Inoue H; Takeuchi H; Kumata K; Zhang MR; Aoki I; Seki C; Ono M; Tokunaga M; Tsukamoto S; Tanabe K; Shin RM; Minamihisamatsu T; Kito S; Richmond BJ; Suhara T; Higuchi M
J Neurosci; 2016 Nov; 36(45):11544-11558. PubMed ID: 27911758
[TBL] [Abstract][Full Text] [Related]
9. Eye-Drops for Activation of DREADDs.
Keenan WT; Fernandez DC; Shumway LJ; Zhao H; Hattar S
Front Neural Circuits; 2017; 11():93. PubMed ID: 29218003
[TBL] [Abstract][Full Text] [Related]
10. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.
Manvich DF; Webster KA; Foster SL; Farrell MS; Ritchie JC; Porter JH; Weinshenker D
Sci Rep; 2018 Mar; 8(1):3840. PubMed ID: 29497149
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity.
Zhan J; Komal R; Keenan WT; Hattar S; Fernandez DC
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31498301
[TBL] [Abstract][Full Text] [Related]
12. Chemogenetic Activation of Excitatory Neurons Alters Hippocampal Neurotransmission in a Dose-Dependent Manner.
Pati S; Salvi SS; Kallianpur M; Vaidya B; Banerjee A; Maiti S; Clement JP; Vaidya VA
eNeuro; 2019; 6(6):. PubMed ID: 31645362
[TBL] [Abstract][Full Text] [Related]
13. CNO Administration Increases Dopamine and Glutamate in the Medial Prefrontal Cortex of Wistar Rats: Further Concerns for the Validity of the CNO-activated DREADD Procedure.
Rodd ZA; Engleman EA; Truitt WA; Burke AR; Molosh AI; Bell RL; Hauser SR
Neuroscience; 2022 May; 491():176-184. PubMed ID: 35351573
[TBL] [Abstract][Full Text] [Related]
14. Validation of DREADD agonists and administration route in a murine model of sleep enhancement.
Ferrari LL; Ogbeide-Latario OE; Gompf HS; Anaclet C
J Neurosci Methods; 2022 Oct; 380():109679. PubMed ID: 35914577
[TBL] [Abstract][Full Text] [Related]
15. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
16. Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.
Saloman JL; Scheff NN; Snyder LM; Ross SE; Davis BM; Gold MS
J Neurosci; 2016 Oct; 36(42):10769-10781. PubMed ID: 27798132
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
Raper J; Morrison RD; Daniels JS; Howell L; Bachevalier J; Wichmann T; Galvan A
ACS Chem Neurosci; 2017 Jul; 8(7):1570-1576. PubMed ID: 28324647
[TBL] [Abstract][Full Text] [Related]
18. Repeated chemogenetic activation of dopaminergic neurons induces reversible changes in baseline and amphetamine-induced behaviors.
Chohan MO; Fein H; Mirro S; O'Reilly KC; Veenstra-VanderWeele J
Psychopharmacology (Berl); 2023 Dec; 240(12):2545-2560. PubMed ID: 37594501
[TBL] [Abstract][Full Text] [Related]
19. Clozapine N-oxide, compound 21, and JHU37160 do not influence effortful reward-seeking behavior in mice.
Aomine Y; Oyama Y; Sakurai K; Macpherson T; Ozawa T; Hikida T
Psychopharmacology (Berl); 2024 Jan; 241(1):89-96. PubMed ID: 37792024
[TBL] [Abstract][Full Text] [Related]
20. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
Lawson KA; Ruiz CM; Mahler SV
Psychopharmacology (Berl); 2023 Oct; 240(10):2101-2110. PubMed ID: 37530882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
